Abstract
Fibronectin was examined for its possible nature as a immunotherapy of cancer. Combined with the known biological response modifier, OK-432, fibronectin was administered locally near the shotted VX2 tongue cancer in rabbits. Fibronectin enhanced the cancer-suppressing effect of OK-432, and the rate of the tumor growth suppression observed was about two-fold that observed for the not fibronectin. The extent of the cancer-suppressing efficacy of fibronectin was positively proportional of the two times (P<0.05). Also, fibronectin in combination with OK-432 significantly suppressed the metastasis to the lymph nodes as compared with the control (P<0.025). These results suggested that fibronectin may be a potentially useful immunotherapy of cancer.
